drugset / Trial / NCT00395629

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

NCT00395629

Phase 1/2 Completed 49 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Brief Summary: This study was designed to explore a safe dose and characterize the preliminary safety and efficacy of ICL670 in adult patients with previously documented history of homozygous C282Y.

Timeline

Start
2006-08
Primary completion
2007-12
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferasirox Unknown 5 mg/kg
Subject Deferasirox Unknown 10 mg/kg
Subject Deferasirox Unknown 15 mg/kg